A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

BACKGROUND: Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown. A phase II clinical trial to investigate the feasibility of intermittent nivolumab dosing was conducted. METHODS: Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornstein, Moshe C., Wood, Laura S., Hobbs, Brian P., Allman, Kimberly D., Martin, Allison, Bevan, Michael, Gilligan, Timothy D., Garcia, Jorge A., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524207/
https://www.ncbi.nlm.nih.gov/pubmed/31097024
http://dx.doi.org/10.1186/s40425-019-0615-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524207/
https://www.ncbi.nlm.nih.gov/pubmed/31097024
http://dx.doi.org/10.1186/s40425-019-0615-z

Ejemplares similares